logo

GRAL

Grail·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

GRAL fundamentals

Grail (GRAL) released its earnings on Nov 12, 2025: revenue was 36.19M (YoY +26.32%), beat estimates; EPS was -2.46 (YoY +37.56%), beat estimates.
Revenue / YoY
36.19M
+26.32%
EPS / YoY
-2.46
+37.56%
Report date
Nov 12, 2025
GRAL Earnings Call Summary for Q3,2025
  • Revenue Growth Accelerates: Q3 2025 U.S. Galleri revenue up 28% YoY, with 45,000 tests sold and 420,000+ cumulative commercial tests.
  • Strategic Expansion: Samsung $110M investment and Canadian launch drive international growth, with FDA PMA submission in Q1 2026.
  • Clinical Excellence: PATHFINDER 2 study shows 7x cancer detection rate vs. standard screening, 61.6% PPV, and 99.6% specificity.
  • Financial Strength: $850M cash, 55% non-GAAP gross margin, and $290M 2025 cash burn (50% YoY decline).
EPS
Revenue

Revenue & Expenses

GRAL has released its 2025 Q3 earnings report, with revenue of 36.19M, reflecting a YoY change of 26.32%, and net profit of -88.98M, showing a YoY change of 29.21%. The Sankey diagram below clearly presents GRAL's revenue sources and cost distribution.

Key Indicators

Grail (GRAL) key financial stats and ratios, covering profitability, financial health, and leverage.
Grail (GRAL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Grail (GRAL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Grail (GRAL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Grail (GRAL) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Grail (GRAL) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield